A study from Yale University today in JAMA Network Open reveals substantial protection by the preventive drug nirsevimab ...

The new research, published Monday (Dec. 9) in the journal JAMA Pediatrics, focused on nirsevimab (Beyfortus), a drug approved in 2023. The medicine, which is given as an injection, uses lab-made ...

The panel voted 21 to zero that Beyfortus (nirsevimab) appears to be safe and effective at preventing RSV infections in newborns and infants as they face their first RSV season, setting the drug ...

Estimated effectiveness was 65% against hospitalization, 74% against pediatric intensive care unit admission, and 64% against ...

but Sanofi is taking the lead on Beyfortus commercially. Sobi also has a profit-sharing interest in the new drug, as part of a 2019 agreement with AZ covering US rights to Synagis. The antibody ...

Getting vaccinated during pregnancy protects your newborn from severe infection during the first critical months of life.

The beyfortus market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX ...